Core Insights - ALK's full-year results for 2025 exceeded expectations, driven by strong Q4 performance and ongoing commercial momentum [1] - The company anticipates sustained organic revenue growth of 11-15% and an EBIT margin of around 25% by 2026, aligning with long-term targets [1][14] - A dividend payment of DKK 355 million, approximately 30% of net profit after tax, is recommended to reward shareholders [1][6] Financial Performance - Q4 2025 revenue reached DKK 1,733 million, a 17% increase compared to the previous year, while full-year revenue grew by 15% to DKK 6,312 million [3][4] - EBIT for Q4 increased by 88% to DKK 387 million, with a margin of 22%, and for the full year, EBIT rose by 53% to DKK 1,654 million, achieving a margin of 26% [3][4] - Free cash flow was positive at DKK 1,432 million, significantly improved from a negative DKK 204 million the previous year [4] Product Performance - Tablet sales increased by 15% to DKK 910 million in Q4, with notable growth in Europe and North America [4] - Sales of SCIT/SLIT drops rose by 11% to DKK 607 million, while anaphylaxis and other products saw a 50% increase to DKK 216 million [4] - Pediatric launches of ACARIZAX and ITULAZAX exceeded expectations, with strong prescriber adoption [5] Strategic Outlook - The company plans to continue double-digit revenue growth and higher earnings in 2026, with a focus on treating more patients with AIT and anaphylaxis products [7][8] - The EBIT margin may experience slight pressure due to a decline in gross margin, offset by higher partner-related sales at lower margins [8] - Ongoing partnerships and clinical trials are expected to contribute positively to future growth [5]

Core Insights - ALK has entered a partnership with Changchun GeneScience Pharmaceutical Co. Ltd. to develop and commercialize its house dust mite allergy immunotherapy products in Mainland China [2][3][10] - GenSci will have exclusive rights to ALK's Alutard HDM product, skin prick tests, and ACARIZAX SLIT-tablet until the end of 2039, while ALK will handle production and supply [3][10] - The partnership aims to accelerate market uptake of ALK's products in China, which has a significant number of individuals suffering from HDM allergies but low treatment penetration [6][10] Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, headquartered in Hørsholm, Denmark, employing around 2,800 people [16] - GenSci is a leading biopharmaceutical company in China with over 9,000 employees, specializing in pediatric and women's health, and is involved in multiple therapeutic areas [17] Financial Implications - The partnership is not expected to materially impact ALK's revenue and earnings in 2025, but is projected to become accretive to earnings margin in the medium term due to savings on capacity costs and clinical expenses [9][10] - ALK will receive an upfront payment of approximately DKK 245 million and is eligible for milestone payments up to DKK 1.3 billion, which will be recognized as revenue over the partnership's duration [12][10] Strategic Goals - GenSci plans to allocate a significant sales force to promote ALK's products and engage in market-building activities, including education and collaborations with healthcare providers [6][10] - Both companies will explore collaboration on innovation for other allergic diseases, with GenSci focusing on the Chinese market and ALK on international markets [8]